[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Baystate Medical Center\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":248},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,48,78,103,134,163,192,219],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100469918","improving-participation-in-pulmonary-rehabilitation-through-peer-support-and-storytelling-100469918",false,"NCT05399056","Improving Participation in Pulmonary Rehabilitation Through Peer Support and Storytelling","ImPReSS-COPD","Inclusion Criteria:\n\n* 40 years or older\n* Received treatment for COPD exacerbation in either inpatient or outpatient setting\n* Referred for pulmonary rehabilitation\n* Ability to understand and communicate in English\n* Willingness to participate in calls with peer coach and to view storytelling videos\n* Working phone\n\nExclusion Criteria:\n\n* Unwilling to attend PR\n* Not eligible for PR based on spirometry or other clinical contraindications as determined by PR staff\n* Currently enrolled in, or completion of 12 or more sessions of PR in the past\n* Comfort measures only or Hospice care\n* Resident of long-term care facility\n* Unable or unwilling to give informed consent","ALL","40 Years",{"count":19,"type":20},305,"ESTIMATED","INTERVENTIONAL",[23],"NA","Chronic Obstructive Pulmonary Disease (COPD) affects approximately 16 million Americans and is characterized by recurrent exacerbations that lead to 1.5 million Emergency Department visits and 700,000 hospitalizations annually. Pulmonary rehabilitation (PR) is a structured program of exercise and self-management support that has been proven to relieve shortness of breath and increase quality of life when initiated after an exacerbation, but unfortunately, few eligible patients participate. This project will compare the effectiveness of two novel strategies - one involving video narratives of other patients telling their story of how they overcame challenges and completed PR, the other involving telephonic peer coaching with an individual with lived experience - to enhanced usual care, and to each other, at increasing patient participation in PR after an exacerbation.",[26],"Chronic Obstructive Pulmonary Disease",[28,29,30,31,32,33,34],"COPD","Pulmonary rehabilitation","Storytelling","Peer coaching","motivational interviewing","Behavioral interventions","chronic obstructive pulmonary disease","RECRUITING","2026-06-03",{"date":38,"type":39},"2026-06-05","ACTUAL",{"date":41,"type":39},"2023-02-24",{"date":43,"type":20},"2027-01-31",{"name":45,"class":46},"Baystate Medical Center","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":55,"minAge":56,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":21,"phases":59,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":47},"100605908","a-type-i-hybrid-effectiveness-implementation-trial-of-mio-100605908","NCT07168642","A Type I Hybrid Effectiveness-Implementation Trial of MIO","A Type I Hybrid Effectiveness-Implementation Trial of Mothering From the Inside Out (MIO)","Client Subjects\n\nInclusion Criteria:\n\n* Identifies as a woman\n* English-speaking\n* Age 18 years or older\n* Enrolled in outpatient substance use treatment for a substance use disorder (by DSMV criteria) at one of the four target clinics operated by participating agencies\n* Caring for at least one child between 0 and 60 months of age (either as guardian or working towards reunification with regular contact)\n\nExclusion Criteria:\n\n* Have severe mental health problems (e.g., actively suicidal, homicidal, psychosis)\n* Severely cognitively impaired\n* Have psychiatric or substance-related symptoms requiring inpatient hospitalization or ambulatory detoxification\n* Unable to speak English\n* Have a potential target child who has a severe medical condition that limits their ability to interact with their mother (such as paralysis or severe weakness)\n\nChildren Subjects\n\nInclusion Criteria:\n\n* Age 5 years or younger\n* Are in their biological mother's custody OR are in custody of family with the goal of reunification with their biological mother and have permission from the child's legal guardian to participate in this study\n\nExclusion Criteria:\n\n•In child welfare custody and goal is not reunification with biological mother\n\nCounselor Subjects\n\nInclusion Criteria:\n\n* Age 21 years or older\n* Employed as an addiction counselor at one of the participating agencies in one of the target clinics\n* Have a bachelor's degree or higher in psychology, social work, counseling, or a related field\n* Have secure administrative approval for a 1-hour per biweekly commitment to supervision and 2-3 hours weekly for MIO delivery\n* Do not intend to give notice and are not scheduled for medical or family leave during the study period\n* Willing to have counseling and supervision sessions recorded\n* Receive a mean score greater than 4 on the Clinical Reflective Functioning Scale\n* Are deemed capable to manage the responsibilities of being a counselor in a randomized trial (deliver MIO promptly to participants, compliant with study procedures and assessments, willing to receive supervision) by their supervisors\n\nExclusion Criteria:\n\n•None\n\nAgency Staff Subjects\n\nInclusion Criteria:\n\n* Employment at a participating agency for at least 3 months\n* Willingness to complete questionnaires and participate in a confidential interview or focus group\n* Fluency in English\n\nExclusion Criteria:\n\n•None","FEMALE","18 Years",{"count":58,"type":20},200,[23],"Mothers with substance use disorders face unprecedented stress in their roles as parents working to care for their children while maintaining healthy recovery. Mothering from the Inside Out (MIO) is the first attachment-based parenting intervention designed specifically for mothers in recovery from substance use disorders that has been shown to have benefit for both mother and child in multiple randomized controlled trials. This project will: (a) test the effectiveness of MIO among women in outpatient treatment under 'real-world' conditions, (b) evaluate implementation in different settings, and (c) assess key implementation factors to support optimal uptake and treatment in future dissemination studies; closing an important science-to-service gap for an underserved population in an effort to support maternal and child health simultaneously.",[62],"Substance Use Disorder",[64,65,66,67,68,69],"substance use disorder","parenting","parenting intervention","Mothering from the Inside Out","MIO","SUD treatment","2026-01-06",{"date":72,"type":39},"2026-01-07",{"date":74,"type":39},"2025-12-18",{"date":76,"type":20},"2029-07-31",{"name":45,"class":46},{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":16,"minAge":56,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":21,"phases":88,"briefSummary":90,"conditions":91,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":47},"100495635","phase-2-smoking-cessation-pharmacotherapy-nurse-practitioner-led-tobacco-treatment-team-study-100495635","NCT05733767","Smoking Cessation Pharmacotherapy-Nurse Practitioner Led Tobacco Treatment Team Study","Implementing Effective Smoking Cessation Pharmacotherapy for Hospitalized Smokers With Cardiopulmonary Disease","STOP-NPT3","Inclusion Criteria:\n\n* Admitted to Baystate Medical Center in Springfield, MA with a cardiac or pulmonary disease diagnosis will be eligible to participate in this trial.\n* Patients who smoke cigarettes\n* Speak English\n\nWe will include any patients with the following diagnoses or procedures from Baystate Medical Center in Springfield, MA:\n\n* myocardial infarction\n* coronary artery bypass grafting surgery\n* heart valve surgery\n* percutaneous coronary intervention (PCI)\n* acute coronary syndrome\n* heart failure\n* chronic obstructive pulmonary disease (COPD)\n* asthma exacerbation.\n\nExclusion Criteria:\n\n* We will exclude pregnant or nursing women, patients with current suicidal ideation, planned discharge to hospice or expected survival \\\u003C6 months, or concurrent use of daily smoked marijuana, because this can increase exhaled carbon monoxide levels, which would confound biochemical confirmation.",{"count":87,"type":20},424,[89],"PHASE2","Tobacco use remains the leading cause of death in the United States and contributes to more than 7 million hospitalizations annually. Being admitted to the hospital offers the perfect opportunity to support smoking cessation. Patients are motivated to quit because of their current illness and societal guidelines recommend clinicians should counsel patients and prescribe smoking cessation pharmacotherapy (SCP) to virtually all smokers.\n\nHowever, only 22% of patients are prescribed SCP while hospitalized, and only 1% are prescribed medications compatible with current guidelines. This failure is part of the reason 70-80% of hospitalized smokers eventually relapse. The relapse typically occurs within a few days of hospital discharge - well before outpatient follow-up can occur.\n\nThe investigators aim to improve smoking cessation treatment and guideline adherence by utilizing the opportunity that hospitalization provides. The investigators have created a tobacco treatment team (T3) to overcome physicians' and patients' low use of current guideline smoking cessation medications. The team members are trained in tobacco treatment and will be led by a nurse practitioner (NPT3). The team will work together and 1) prescribe individually tailored and guideline-concordant SCP; 2) counsel and motivate patients to use SCP properly; and 3) manage a mobile phone-based text-messaging system to keep patients motivated and adherent to SCP. Our preliminary data suggest that such an approach is workable and acceptable to patients, physicians, and hospital administrators.\n\nThe investigators will recruit 424 patients in the hospital who smoke with cardiopulmonary disease. These patients will be randomized to receive either usual care or personalized care with the NPT3 team. The investigators will compare rates of guideline-concordant SCP use at 1 week and exhaled carbon monoxide (eCO) verified smoking cessation at 6 months between patients randomized to the NPT3 team vs. usual care.\n\nThe investigators will also measure the project's economic value from a hospital and payer perspective. Understanding the economic value will better inform hospital and insurance policies and sustainability. Finally, acceptability, generalizability, and sustainability measures will be assessed through qualitative interviews with patients, providers, and hospital leadership.",[92,93,94],"Cardiopulmonary Disease","Smoking Cessation","Inpatient","2025-12-23",{"date":97,"type":39},"2025-12-30",{"date":99,"type":39},"2022-11-03",{"date":101,"type":20},"2027-12-30",{"name":45,"class":46},{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":107,"acronym":108,"eligibilityCriteria":109,"healthyVolunteers":110,"sex":16,"minAge":111,"maxAge":112,"enrollmentInfo":113,"targetDuration":4,"studyType":21,"phases":115,"briefSummary":116,"conditions":117,"keywords":120,"overallStatus":125,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":4},"100605907","a-community-health-worker-intervention-to-improve-lung-cancer-screening-uptake-in-community-health-centers-100605907","NCT07168629","A Community Health Worker Intervention to Improve Lung Cancer Screening Uptake in Community Health Centers","CHATS","Inclusion Criteria:\n\n* Adults between the age of 50 and 80.\n* Potentially eligible for LCS according to the Electronic Health Record smoking history.\n* Receive their primary care at Mason Square, High Street, or Brightwood community health centers.\n* English- or Spanish- speaking.\n\nExclusion Criteria:\n\n* Not eligible for lung cancer screening based on age (age \\\u003C 50 or \\> 80 years) or smoking history (has not smoked more than 20 pack-years of tobacco cigarettes or quit more than 15 years ago).\n* Have received a lung cancer screen in the past.",true,"50 Years","80 Years",{"count":114,"type":20},80,[23],"Lung cancer screening (LCS) can reduce lung cancer-related mortality by 20%, but only 5-10% of eligible individuals have received an initial LCS. The goal of this study is to partner with community stakeholders to jointly develop and pilot test a multi-component community health worker-delivered intervention targeting key barriers to improve LCS and tobacco treatment utilization. The proposed activities will lay the groundwork for a subsequent R01 grant, conducting a fully powered randomized clinical trial to establish CHWs as an evidence-based practice that will facilitate access to screening and tobacco treatment, to reduce lung cancer mortality.",[118,119],"Lung Cancer","Tobacco Use",[121,122,123,124],"lung cancer screening","tobacco treatment","community health workers","community health centers","NOT_YET_RECRUITING","2025-09-04",{"date":128,"type":39},"2025-09-11",{"date":130,"type":20},"2025-10-01",{"date":132,"type":20},"2028-08-01",{"name":45,"class":46},{"id":135,"slug":136,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":140,"eligibilityCriteria":141,"healthyVolunteers":11,"sex":16,"minAge":142,"maxAge":143,"enrollmentInfo":144,"targetDuration":4,"studyType":21,"phases":146,"briefSummary":147,"conditions":148,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":162},"100510376","phase-2-improving-cardiac-rehabilitation-exercise-using-target-heart-rate-trial-100510376","NCT05925634","Improving Cardiac Rehabilitation Exercise Using Target Heart Rate Trial","Improving Outcomes From Cardiac Rehabilitation Among Older Adults Through Exercise Testing and Individualized Exercise Intensity Prescriptions","PACE SETTER","Inclusion Criteria:\n\n* Patients who are eligible for cardiac rehabilitation by having had a cardiac event such as a myocardial infarction (heart attack), heart failure, percutaneous coronary intervention or angioplasty with stent, coronary artery bypass graft, or heart valve surgery in the past 6 months.\n* Lives in, or plans to reside in, the Springfield, MA, or greater Detroit, MI, area for the next year.\n* Recruited from a Phase 2 Cardiac Rehabilitation Center at either Baystate Medical Center or Henry Ford Health System.\n* Age ≥ 60 years\n* Agrees to attend at least 18 sessions of cardiac rehabilitation after randomization\n* Agrees to attend cardiac rehabilitation at least twice a week\n\nExclusion Criteria: These include conditions that alter the physiology and monitoring of resting and exercise heart rate. These also include conditions that might limit an individual's ability to exercise.\n\n* Permanent atrial fibrillation\n* Heart transplant\n* Left-ventricular assist devices\n* Stable angina\n* High-risk un-revascularized coronary artery disease\n* Symptomatic peripheral artery disease\n* Aortic and\u002For mitral stenosis\n* Any condition where exercise testing or training might be unsafe or limited","60 Years","99 Years",{"count":145,"type":20},320,[89],"The goal of this clinical trial is to compare two types of exercise prescriptions in cardiac rehabilitation eligible older adults (60 years or older) with heart disease. The investigators found in a single site pilot trial (insert NCTxxx) that one exercise prescription was better and are now repeating this study in a larger population at two sites (Baystate Medical Center, Springfield MA and Henry Ford Health System, Detroit MI). The main questions the investigators aim to answer are:\n\n1. Compare two different exercise prescriptions in cardiac rehabilitation on exercise outcomes\n\n   1. Graded exercise test +Target heart rate range prescription \\[GXT-THRR\\]\n   2. Rating of perceived exertion (RPE)\n2. What is the role of psychological feedback on fitness outcomes during cardiac rehabilitation and physical activity outside of cardiac rehabilitation.\n3. What are the long-term clinical outcomes between the two exercise prescriptions\n\nParticipants will be asked to:\n\n* Complete surveys about physical activity, exercise anxiety, exercise efficacy, and fears about exercising\n* Perform fitness measures (6-minute walk test, balance tests, stand to sit tests, a 400 meter walk, and handgrip strength)\n* Attend at least 18 sessions of cardiac rehabilitation after they are randomized to their exercise prescription group\n* Wear a heart rate monitor and a physical activity monitor per study protocol\n\nParticipants will be randomized (flip of a coin) to either receive a graded exercise test and psychoeducational feedback or lifestyle education (nutrition for cardiac). The graded exercise test will be used to create a personalized exercise prescription with the target heart rate range calculated from the test and the lifestyle education group will use their ratings of perceived exertion for their exercise prescription.",[149,150,151,152,153],"Myocardial Infarction","Coronary Artery Bypass","Percutaneous Coronary Intervention","Heart Failure","Cardiac Valve Surgery","2025-07-04",{"date":156,"type":39},"2025-07-09",{"date":158,"type":39},"2023-08-10",{"date":160,"type":20},"2027-06-30",{"name":45,"class":46},2,{"id":164,"slug":165,"hasResults":11,"nctId":166,"briefTitle":167,"officialTitle":168,"acronym":4,"eligibilityCriteria":169,"healthyVolunteers":11,"sex":16,"minAge":56,"maxAge":4,"enrollmentInfo":170,"targetDuration":4,"studyType":21,"phases":172,"briefSummary":173,"conditions":174,"keywords":180,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":185,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":191,"locationsCount":47},"100594439","physician-modified-endovascular-grafts-for-the-treatment-of-elective-symptomatic-or-ruptured-juxtarenal-aortic-aneurysms-100594439","NCT07019454","Physician Modified Endovascular Grafts for the Treatment of Elective, Symptomatic or Ruptured Juxtarenal Aortic Aneurysms","Baystate Health Physician Sponsored - Investigational Device Exception: Physician Modified Endovascular Grafts for the Treatment of Elective, Symptomatic or Ruptured Juxtarenal Aortic Aneurysms","Inclusion Criteria:\n\n1. Patient is ≥ 18 years of age\n2. Patients who are male or non-pregnant female (females of child bearing potential must have a negative pregnancy test prior to enrollment into the study)\n3. Patient or Legally Authorized Representative has signed an Institutional Review Board (IRB) approved Informed Consent Form\n4. Patient has a juxtarenal abdominal aortic aneurysm that meets at least one of the following:\n\n   1. An aneurysm with a maximum diameter of ≥ 5.5 cm for male (≥ 5.0 cm for female) or 2 times the normal diameter just proximal to the aneurysm using orthogonal (i.e., perpendicular to the centerline) measurements\n   2. Aneurysm with a history of growth \\> 0.5 cm in 6 months\n   3. Saccular aneurysm deemed at significant risk for rupture\n   4. Symptomatic aneurysm\n   5. Ruptured aneurysm\n5. Patient has patent iliac or femoral arteries, with or without the use of conduit, that will allow endovascular access with the physician modified endovascular graft.\n6. Patient has a suitable non-aneurysmal proximal aortic neck of ≥ 2 mm inferior to the most distal renal artery ostium.\n7. Patient has a suitable non-aneurysmal distal iliac artery length (seal zone) of ≥ 15mm. The resultant repair should preserve patency in at least one hypogastric artery.\n8. Patient has a suitable non-aneurysmal proximal aortic neck diameter between 20 and 32 mm, averaged across the diameters at the Celiac, SMA, at the lowest patent renal artery and at the midpoint of the renal arteries.\n9. Patient has suitable non-aneurysmal distal common iliac diameters between 8 and 20 mm.\n10. Patient has juxtarenal aortic neck angulation ≤ 60°\n11. Target branch vessel diameter ≥ 5 mm.\n12. Patient must be willing to comply with all required follow-up exams.\n\nExclusion Criteria:\n\n1. Patient has a mycotic aneurysm or has an active systemic or local infection that may increase the risk of endovascular infection\n2. Patient has unstable angina (defined as angina with a progressive increase in symptoms, new onset at rest or nocturnal angina, or onset of prolonged angina)\n3. Patient has a major surgical or interventional procedure, not related to the endovascular repair, planned within +\u002F- 30 days of the AAA repair.\n4. Patient has history of an aortopathic connective tissue disease (e.g. Marfan's or Ehler's- Danlos syndrome).\n5. Patient has a known hypersensitivity or contraindication to anticoagulation or contrast media that is not amenable to pre-treatment.\n6. Patient has known allergy or intolerance to stainless steel, nitiol, or gold (gold-plated tungsten)\n7. Patient has a body habitus that would inhibit X-ray visualization of the aorta\n8. Patient has a limited life expectancy of less than 1 year\n9. Patient is currently participating in another investigational device or drug clinical trial\n10. Patient has other medical, social or psychological conditions that, in the opinion of the investigator, preclude them from receiving the pre-treatment, required treatment, and post- treatment procedures and evaluations.\n11. Thrombus or excessive calcification within the neck of the aneurysm\n12. Branch vessel stenosis ≥ 80 %\n13. Patients treatable on label with FDA approved EVAR or FEVAR device and can wait for device availability.\n14. Subject is willing and eligible to enroll in a manufacturer-sponsored study at the investigational site, or the subject is willing and eligible to participate in a study with a manufacturer-made device at another institution.",{"count":171,"type":20},15,[23],"Patients who are found to have an aneurysm (bulge) in the abdominal aorta, which is the blood vessel in your abdomen (belly) that supplies blood to most of your lower body, including major organs and your legs. As an aneurysm expands, the walls of the aorta become weak and may rupture (break open), causing a major loss of blood with a high risk of serious problems and death. To avoid this risk, doctors repair aneurysms by either open surgery (incision) or endovascular surgery (covered stents to channel the blood flow). Juxtarenal aneurysms (those that come close to the kidney arteries) present a unique challenge as they are more dangerous to repair by open therapy and do not fit the standard approved endovascular devices. The purpose of this study is to assess the effects of the physician-modified endovascular graft (PMEG) by collecting information about the performance of this investigational medical device.\n\nThe main graft looks like a pair of pants with very short legs. The top of the pants is placed in the aorta. Then, two smaller grafts go from the main graft and to your iliac arteries (the main arteries supplying blood to your abdomen and legs) to form the legs of the pair of pants. Each graft is packed into a small catheter (a long, flexible plastic tube) that is placed into your aorta through the femoral artery in your groin (top of your leg). The grafts are then placed in the correct position in your aorta by releasing them from the catheters. These grafts are investigational because the research physician has changed them to match patient anatomy (body make up) while protecting blood flow to important vessels. Once the grafts are attached inside the aorta, they will support the area of the aorta that is weakened and bulging.\n\nModifications of the graft will include between one and four holes (fenestrations) near the top of the graft. The holes allow the graft to be located above the renal arteries (the blood vessels that supply blood to your kidneys) without blocking the blood flow to them. One or more of the arteries will also be treated with a stent (metal wire tube) to help keep the arteries open and to keep the arteries connected to the holes that are made for the graft.\n\nThe device is custom modified for patient specific anatomy. The information collected from this study will be used to show how well patients do when treated with the modified graft, both immediately after surgery and over a long period of time. After the procedure, labs, CT imaging with contrast, XRays and ultrasounds will be done to check the graft at intervals 1 month, 6 months, 12 months and yearly for 5 years. These are standard surveillance studies performed on any endovascular aneurysm repair.",[175,176,177,178,179],"Technical Sucess","Freedom From Type I and III Endoleaks at 12 Months","Freedom From Stent Graft Migration at 12 Months","Freedom From Aortic Aneurysm Enlargement at 12 Months","Freedom From Aortic Aneurysm Rupture or Conversion to Open Repair at 12 Months",[181,182,183],"complex endovascular aortic aneurysm repair","PMEG","juxtarenal","2025-06-12",{"date":186,"type":39},"2025-06-13",{"date":188,"type":39},"2025-06-03",{"date":190,"type":20},"2035-06-03",{"name":45,"class":46},{"id":193,"slug":194,"hasResults":11,"nctId":195,"briefTitle":196,"officialTitle":197,"acronym":198,"eligibilityCriteria":199,"healthyVolunteers":11,"sex":16,"minAge":56,"maxAge":4,"enrollmentInfo":200,"targetDuration":4,"studyType":21,"phases":202,"briefSummary":203,"conditions":204,"keywords":206,"overallStatus":125,"whyStopped":4,"lastUpdateSubmitDate":211,"lastUpdatePostDateStruct":212,"startDateStruct":214,"completionDateStruct":216,"leadSponsor":218,"locationsCount":47},"100165088","phase-2-minocycline-plus-amiodarone-versus-amiodarone-alone-for-the-prevention-of-atrial-fibrillation-after-cardiac-surgery-100165088","NCT01422148","Minocycline Plus Amiodarone Versus Amiodarone Alone for the Prevention of Atrial Fibrillation After Cardiac Surgery","Minocycline Plus Amiodarone Versus Amiodarone Alone for the Prevention of Atrial Fibrillation After Cardiac Surgery (MINA)","MINA","Inclusion criteria are adults, including women and minorities \\> 18 years of age, who are also willing to participate for the duration of the trial (6 weeks). All non-congenital cardiac operations are included: Coronary Artery Bypass Graft, valve repair\u002Freplacement, or combination of CABG and heart valve operations. Patients should be able to access iPhones and download ECGs using their electronic Devices. Exclusion criteria Patients with prior (within 6 months) or current atrial fibrillation (AF) or flutter, patients undergoing concomitant surgical AF ablation or a history of AF, transcatheter aortic valve replacement or other minimally invasive procedures, prior cerebrovascular event, cardiogenic shock or resuscitation, evidence of hepatic or renal dysfunctions (i.e., an alanine aminotransferase level that is ≥ twice the upper limit of the normal range, or either a serum creatinine level that is ≥ 2.0 mg\u002FdL or need for preoperative dialysis) are excluded. Other exclusion criteria are the following: thyrotoxicosis, pregnancy, severe chronic obstructive pulmonary disease (COPD, with FEV1\u002FFVC \\\u003C70%), recent history of drug or alcohol abuse, and intolerance to tetracycline or amiodarone. Because a core scientific basis of this trial concerning the role of underlying atrial tissue inflammatory\u002Fapoptotic activity, patients with inflammatory conditions such as lupus, severe arthritis, thyroiditis or inflammatory bowel disease are excluded; as are patients taking preoperative immunosuppressant agents, long-term (\\>10 days) oral corticosteroids (prednisolone \\> 10mg or other), or estrogen replacement; and finally patients with newly diagnosed cancer (\\\u003C5 years) are also excluded.",{"count":201,"type":20},60,[89],". New- onset postoperative atrial fibrillation (POAF) is a common complication after cardiac surgery and its occurrence increases with age. POAF can result in clinically significant morbidity and mortality. The national trend in the US is that the population older than 65 years is increasing, making healthcare expenditure related to POAF to be a major burden on health care system. Effective treatment of POAF is imperative in ensuring quality of care and reduction of costs.\n\nIn 2021 there is a projected total of 377,763 cardiovascular surgeries in the US alone with approximately half of which will have POAF with longer postoperative length of stay (+3.9 days) and higher discharge costs (+$13,993) than no-POAF patients (Reference: Ann Thorac Surg. 2015 Jan;99(1):109-14). Amiodarone, the currently used therapy, is often insufficient to prevent POAF and has multiple side-effects. In this study, we expect to improve the incidence of POAF by using a common acne drug (Minocycline) that is safe and that could be incorporated in clinical care of this disease.",[205],"Atrial Fibrillation",[207,208,209,210],"cardiac surgery","atrial fibrillation","minocycline","amiodarone","2024-08-05",{"date":213,"type":39},"2024-08-06",{"date":215,"type":20},"2025-07",{"date":217,"type":20},"2028-01-24",{"name":45,"class":46},{"id":220,"slug":221,"hasResults":11,"nctId":222,"briefTitle":223,"officialTitle":224,"acronym":225,"eligibilityCriteria":226,"healthyVolunteers":11,"sex":16,"minAge":56,"maxAge":4,"enrollmentInfo":227,"targetDuration":4,"studyType":21,"phases":229,"briefSummary":230,"conditions":231,"keywords":233,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":240,"lastUpdatePostDateStruct":241,"startDateStruct":243,"completionDateStruct":245,"leadSponsor":247,"locationsCount":47},"100556647","aim-2---conversations-can-save-lives-talking-about-buprenorphine--methadone-for-opioid-use-treatment-initiation-100556647","NCT06527820","Aim 2 - Conversations Can Save Lives: TALKing About Buprenorphine & Methadone for Opioid Use Treatment Initiation","Aim 2 - Conversations Can Save Lives: TALKing About Buprenorphine & Methadone for Opioid Use Treatment Initiation (TALK ABOUT It)","TalkAboutIt","Inclusion Criteria:\n\n* Patients aged 16 and older\n* presenting with indications for Medications for Opioid Use Disorder (MOUD) initiation (opioid overdose, opioid withdrawal, complications of injection opioid use, untreated OUD)\n* not currently on buprenorphine or methadone (in the past 7 days).\n\n(Buprenorphine is FDA approved for patients aged 16 and older, so 16- and 17-year-olds may be included with parental consent.)\n\nExclusion Criteria:\n\n* No Opioid Use Disorder (OUD)\n* already on MOUD",{"count":228,"type":20},75,[23],"The increasing morbidity and mortality of the opioid epidemic has necessitated a reevaluation of current addiction treatment paradigms: medications for opioid use disorder, such as buprenorphine and methadone, are effective in decreasing one's risk of death and disability from opioid use, but are underutilized and often difficult to access. The 5000 Emergency Departments (EDs) in the US are potential additional locales for medication initiation, but currently only a small minority of ED patients with opioid use disorder are started on medications. This study will refine and pilot an intervention called Talk About It which aims to foster patient-centered care, 'meet patients where they are' for addiction treatment, and increase treatment initiation and adherence via facilitating Shared Decision-Making in the ED around these potentially life-saving options.",[232],"Opioid Use Disorder",[234,235,236,237,238,239],"shared decision-making","decision aid","conversation aid","patient-centered care","addiction","emergency medicine","2024-07-30",{"date":242,"type":39},"2024-07-31",{"date":244,"type":39},"2024-06-01",{"date":246,"type":20},"2026-08-30",{"name":45,"class":46},""]